Literature DB >> 2350096

Effects of buspirone on sleep and respiration.

W B Mendelson1, J V Martin, D M Rapoport.   

Abstract

Drugs used in the treatment of anxiety are frequently sedating and tend to be respiratory depressants. Buspirone, a nonbenzodiazepine anxiolytic agent, has little reported sedative effect. It has been shown to be a respiratory stimulant in an anesthetized, glomectomized cat model. In this study, we examined the effects of two intraperitoneal single doses (10 and 20 mg/kg) of buspirone on sleep and respiration in unanesthetized, intact, freely moving rats. Buspirone increased sleep latency (p less than 0.0001) and decreased total sleep (p less than 0.02) through reductions in both non-REM and REM sleep. Respiratory rate (p less than 0.0003) and ventilation (p less than 0.004) were significantly increased for 4 h after drug injection. The effects on respiration were independent of those on sleep; stimulation was evident in both waking and non-REM sleep. This study suggests that buspirone, in addition to being free of sedating and respiratory depressant side effects when prescribed for anxiety in humans, may be a respiratory stimulant whose effects persist in sleep.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2350096     DOI: 10.1164/ajrccm/141.6.1527

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

Review 1.  Management of dyspnea in patients with chronic obstructive pulmonary disease.

Authors:  Amy P Abernethy; Hope E Uronis; Jane L Wheeler; David C Currow
Journal:  Wien Med Wochenschr       Date:  2009-12

2.  The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects.

Authors:  H S Driver; M J Flanigan; A J Bentley; H G Luus; C M Shapiro; D Mitchell
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

3.  Effects of buspirone on posthypoxic ventilatory behavior in the C57BL/6J and A/J mouse strains.

Authors:  Motoo Yamauchi; Jesse Dostal; Hiroshi Kimura; Kingman P Strohl
Journal:  J Appl Physiol (1985)       Date:  2008-05-29

4.  Buspirone decreases susceptibility to hypocapnic central sleep apnea in chronic SCI patients.

Authors:  Scott Maresh; Joel Prowting; Sarah Vaughan; Elizabeth Kruppe; Bander Alsabri; Hossein Yarandi; M Safwan Badr; Abdulghani Sankari
Journal:  J Appl Physiol (1985)       Date:  2020-08-20

Review 5.  Countermeasures for Preventing and Treating Opioid Overdose.

Authors:  Charles P France; Gerard P Ahern; Saadyah Averick; Alex Disney; Heather A Enright; Babak Esmaeli-Azad; Arianna Federico; Lisa R Gerak; Stephen M Husbands; Benedict Kolber; Edmond Y Lau; Victoria Lao; David R Maguire; Michael A Malfatti; Girardo Martinez; Brian P Mayer; Marco Pravetoni; Niaz Sahibzada; Phil Skolnick; Evan Y Snyder; Nestor Tomycz; Carlos A Valdez; Jim Zapf
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.875

6.  Adverse Respiratory Events Associated With Hypnotics Use in Patients of Chronic Obstructive Pulmonary Disease: A Population-Based Case-Control Study.

Authors:  Wei-Sheng Chung; Ching-Yuan Lai; Cheng-Li Lin; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

7.  Research Priorities for Patients with Heart Failure and Central Sleep Apnea. An Official American Thoracic Society Research Statement.

Authors:  Jeremy E Orr; Indu Ayappa; Danny J Eckert; Jack L Feldman; Chandra L Jackson; Shahrokh Javaheri; Rami N Khayat; Jennifer L Martin; Reena Mehra; Matthew T Naughton; Winfried J Randerath; Scott A Sands; Virend K Somers; M Safwan Badr
Journal:  Am J Respir Crit Care Med       Date:  2021-03-15       Impact factor: 21.405

Review 8.  Palliative management of refractory dyspnea in COPD.

Authors:  Hope E Uronis; David C Currow; Amy P Abernethy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.